Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **miR-145 lentiviral vector** is a gene therapy research tool and experimental pharmaceutical based on a recombinant lentiviral vector engineered to express the microRNA miR-145. This construct is used to deliver and induce stable overexpression of miR-145 in target cells for preclinical or laboratory investigation. miR-145 functions as a tumor suppressor microRNA and its overexpression via lentiviral delivery has been shown to inhibit cancer cell proliferation, migration, invasion, EMT (epithelial-mesenchymal transition), stemness of cancer stem cells, and to induce apoptosis across various tumor models including liver cancer stem cells and esophageal carcinoma cells[1][2]. In metabolic disease models, lentiviral miR-145 reduces inflammatory pathways, macrophage infiltration, and improves glucose metabolism, partly by targeting OPG, KLF5, and downregulating NF-κB activation[3]. In liver cancer, it targets COL4A3 and modulates the Wnt/β-catenin and autophagy pathways[1]. The miR-145 lentiviral vector is most often used in research settings for both in vitro and in vivo studies and is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-145 lentiviral vector.